Literature DB >> 24802407

miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1.

Zhengyu Xu1, Tao Wang2.   

Abstract

Previous studies have shown that miR-214 functions either as an oncogene or a tumor suppressor in various human cancer types. The role of this microRNA in osteosarcoma (OS) is presently unclear. Here, we demonstrated that miR-214 is frequently upregulated in OS specimens, compared with noncancerous bone tissues. Bioinformatics analysis further revealed leucine zipper, putative tumor suppressor 1 (LZTS1) as a potential target of miR-214. Expression patterns of miR-214 were inversely correlated with those of LZTS1 mRNA and protein in OS tissues. Data from reporter assays showed that miR-214 directly binds to the 3'-untranslated region (3'-UTR) of LZTS1 mRNA and suppresses expression at both transcriptional and translational levels. In functional assays, miR-214 promoted OS cell proliferation, invasion and tumor growth in nude mice, which could be reversed by overexpression of LZTS1. Taken together, our data provide compelling evidence that miR-214 functions as an onco-miRNA in OS, and its oncogenic effects are mediated chiefly through downregulation of LZTS1.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  LZTS1; Osteosarcoma; miR-214

Mesh:

Substances:

Year:  2014        PMID: 24802407     DOI: 10.1016/j.bbrc.2014.04.140

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

1.  miRNA-449a is downregulated in osteosarcoma and promotes cell apoptosis by targeting BCL2.

Authors:  Jie Chen; Jinsong Zhou; Xin Chen; Baohui Yang; Dong Wang; Pinglin Yang; Xijing He; Haopeng Li
Journal:  Tumour Biol       Date:  2015-05-23

Review 2.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

3.  Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7.

Authors:  Yongzheng Bao; Bin Chen; Qiang Wu; Konghe Hu; Xinhua Xi; Wengang Zhu; Xueren Zhong; Jianting Chen
Journal:  Clin Exp Med       Date:  2015-10-29       Impact factor: 3.984

4.  Down-regulation of microRNA152 is associated with the diagnosis and prognosis of patients with osteosarcoma.

Authors:  Nai-Guo Wang; Da-Chuan Wang; Bing-Yi Tan; Feng Wang; Ze-Nong Yuan
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 5.  Review of microRNA in osteosarcoma and chondrosarcoma.

Authors:  Le Chang; Swati Shrestha; Greg LaChaud; Michelle A Scott; Aaron W James
Journal:  Med Oncol       Date:  2015-04-26       Impact factor: 3.064

6.  MiR-214 suppressed ovarian cancer and negatively regulated semaphorin 4D.

Authors:  Yang Liu; Honglin Zhou; Lan Ma; Youfang Hou; Jing Pan; Chunyi Sun; Yingying Yang; Jie Zhang
Journal:  Tumour Biol       Date:  2015-12-30

Review 7.  miR-214 as a key hub that controls cancer networks: small player, multiple functions.

Authors:  Elisa Penna; Francesca Orso; Daniela Taverna
Journal:  J Invest Dermatol       Date:  2014-12-11       Impact factor: 8.551

8.  miR-214-3p promotes the proliferation, migration and invasion of osteosarcoma cells by targeting CADM1.

Authors:  Haiqing Cai; Mingyuan Miao; Zhigang Wang
Journal:  Oncol Lett       Date:  2018-06-08       Impact factor: 2.967

9.  LncRNA BCRT1 facilitates osteosarcoma progression via regulating miR-1303/FGF7 axis.

Authors:  Gang Han; Quanyi Guo; Ning Ma; Wenzhi Bi; Meng Xu; Jinpeng Jia; Wei Wang
Journal:  Aging (Albany NY)       Date:  2021-06-08       Impact factor: 5.682

10.  Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma.

Authors:  Wendy Allen-Rhoades; Lyazat Kurenbekova; Laura Satterfield; Neha Parikh; Daniel Fuja; Ryan L Shuck; Nino Rainusso; Matteo Trucco; Donald A Barkauskas; Eunji Jo; Charlotte Ahern; Susan Hilsenbeck; Lawrence A Donehower; Jason T Yustein
Journal:  Cancer Med       Date:  2015-03-17       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.